Inovio Pharmaceuticals, Inc. (NYSEMKT:INO) was a big mover last session, as the company saw its shares shoot up nearly 13% on the day. This rally higher can be attributable to solid volume with far more shares changing hands than in a normal session. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) shares after opening at $3.22 moved to $3.64 on last trade day and at the end of the day closed at $3.28. Company price to sales ratio in past twelve months was calculated as 50.74 and price to cash ratio as 13.02. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) showed a negative weekly performance of -11.11%.
Analysts at MLV & Co. cut their price objective on shares of Galena Biopharma (NASDAQ:GALE) from $6.00 to $5.00 in a research report issued to clients and investors on Thursday, Analyst Ratings.Net reports. MLV & Co.‘s target price indicates a potential upside of 71.23% from the stock’s previous close. Galena Biopharma Inc. (NASDAQ:GALE) shares fell -6.29% in last trading session and ended the day on $2.22. GALE return on equity ratio is recorded as -435.40% and its return on assets is -113.60%. Galena Biopharma Inc. (NASDAQ:GALE) yearly performance is 5.71%.
Celldex Therapeutics (NASDAQ:CLDX) had its target price reduced by Oppenheimer from $40.00 to $36.00 in a report issued on Tuesday, ARN reports. They currently have an outperform rating on the stock. Celldex Therapeutics, Inc. (NASDAQ:CLDX) shares moved down -8.92% in last trading session and was closed at $16.95, while trading in range of $16.86 – $18.97. Celldex Therapeutics, Inc. (NASDAQ:CLDX) year to date (YTD) performance is -29.99%.
Biogen Idec Inc. (NASDAQ:BIIB) has won U.S. approval for its long-acting hemophilia B treatment Alprolix, the U.S. Biogen Idec Inc. (NASDAQ:BIIB) weekly performance is -7.66%. On last trading day company shares ended up $294.12. Biogen Idec Inc. (NASDAQ:BIIB) distance from 50-day simple moving average (SMA50) is -9.21%. Analysts mean target price for the company is $345.52.
Leave a Reply